Chiron shareholders embrace Novartis
This article was originally published in The Gray Sheet
Executive Summary
More than 85% of Chiron's total outstanding shares were cast in favor of Novartis' $5.1 bil. bid to acquire the blood test and vaccine producer on April 19. The merger, already cleared by the FTC and European Commission, closed the next day...